STILSEMA
LIVE

Serial Number

97477162

Owner

Teva Pharmaceuticals USA

Attorney

Lori Wolfe

Filing Date

Jun 27, 2022

Add to watchlist:

No watchlists yet
View on USPTO

STILSEMA Trademark

Serial Number: 97477162

STILSEMA is a trademark filed by Teva Pharmaceuticals USA on June 27, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Teva Pharmaceuticals USA (12 trademarks)

400 Interpace Parkway
Parsippany, NJ 07054

Entity Type: 03

Trademark Details

Filing Date

June 27, 2022

Registration Date

Not Registered

Published for Opposition

May 16, 2023

Goods & Services

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations, namely, oral and injectable contraceptives, women's hormone replacement medications

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 10, 2026 EXRA
SOU EXTENSION 5 GRANTED
Mar 9, 2026 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 9, 2026 AITU
SOU EXTENSION RECEIVED WITH TEAS PETITION
Feb 18, 2026 TPEX
NOTICE OF REVIVAL - E-MAILED
Feb 18, 2026 NREV
PETITION TO REVIVE-GRANTED
Feb 18, 2026 PETG
TEAS PETITION TO REVIVE RECEIVED
Feb 18, 2026 PROA
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Feb 16, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Feb 16, 2026 ABN6
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 21, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 21, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 21, 2026 REAP
SOU EXTENSION 5 FILED
Jan 12, 2026 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 27, 2025 EXRA
SOU EXTENSION 4 GRANTED
Jun 26, 2025 EX4G
SOU EXTENSION 4 FILED
Jun 26, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 26, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 18, 2024 EXRA
SOU EXTENSION 3 GRANTED
Dec 18, 2024 EX3G
SOU EXTENSION 3 FILED
Dec 18, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 18, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 10, 2024 EXRA
SOU EXTENSION 2 GRANTED
Jul 10, 2024 EX2G
SOU EXTENSION 2 FILED
Jul 10, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 10, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 6, 2024 EXRA
SOU EXTENSION 1 GRANTED
Jan 4, 2024 EX1G
SOU EXTENSION 1 FILED
Jan 4, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 4, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 11, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 16, 2023 NPUB
PUBLISHED FOR OPPOSITION
May 16, 2023 PUBO
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 4, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 4, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 4, 2023 REAP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 26, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 12, 2023 CNSA
ASSIGNED TO EXAMINER
Apr 11, 2023 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 22, 2023 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Feb 22, 2023 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 22, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 22, 2023 REAP
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 14, 2022 NWOS
NEW APPLICATION ENTERED
Jun 30, 2022 NWAP